ZBIO
NASDAQ
US
Zenas BioPharma, Inc. - Common Stock
$21.46
▲ +$1.10
(+5.40%)
Vol 1.7M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.3B
ROE
-73.6%
D/E
37.16
Beta
0.61
52W
$6–$45
Wall Street Consensus
14 analysts · Apr 20267
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
PGEN
Precigen Inc
$1.5B
GLUE
Monte Rosa Therapeutics Inc
P/E 48.7
$1.0B
BCAX
Bicara Therapeutics Inc
$922.0M
OLMA
Olema Pharmaceuticals Inc
$2.0B
TSHA
Taysha Gene Therapies Inc
$1.5B
NVAX
Novavax Inc
P/E 3.2
$1.1B
CRVS
Corvus Pharmaceuticals Inc
$575.1M
SVRA
Savara Inc
$1.2B
AVBP
ArriVent BioPharma Inc
$830.6M
Earnings
Beat rate: 20.0%
Next Report
May 13, 2026
EPS Estimate: $-1.31
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.31 | — | — |
| Dec 2025 | $-1.05 | $-4.54 | $-3.49 |
| Sep 2025 | $-1.07 | $-1.22 | $-0.15 |
| Jun 2025 | $-1.07 | $-1.25 | $-0.18 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -59.2% | -59.2% | -59.2% | -59.2% | -73.6% | -73.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 37.16 | 37.16 |
| Current Ratio | 5.23 | 5.23 | 5.23 | 5.23 | 5.66 | 5.66 |
Key Ratios
ROA (TTM)
-57.6%
P/B
1.1
EPS (TTM)
$-12.67
52W High
$44.60
52W Low
$5.83
$5.83
52-Week Range
$44.60
How does ZBIO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ZBIO valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.1
▼
55%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ZBIO profitability vs Biotechnology peers
ROE
-73.6%
▼
9%
below
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-57.6%
▼
23%
below
peers
(-46.7%)
vs Peers
vs Industry
Below avg
ZBIO financial health vs Biotechnology peers
D/E ratio
37.2
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
5.7
▲
27%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.6
▼
37%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ZBIO fundamentals radar
ZBIO
Peer median
Industry
ZBIO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio